PRESS RELEASE

AFFiRiS AG successfully raises €10 m equity financing

€ 10m additional capital raised

Vienna, 2nd May 2017. AFFiRiS AG has successfully completed its capital increase and raises an additional €10m from existing investors.

In an annual general meeting on 25th April 2017 the shareholders of the company have agreed to a capital increase of €10m. The new shares have been subscribed by the two major investors of the company, Santob Holding – the family office of the Strüngmann family – the MIG Funds advised by MIG Verwaltungs AG and the FCPB Affi GmbH.

AFFIRIS commenced Phase 1 clinical development of its Hypercholesterolemia and Atherosclerosis prevention active immunotherapy candidates AT04A and AT06A and expects data from this study in Q2 2017. AT04A and AT06A are vaccine candidates from the next generation AFFITOME® technology and target PCSK9, an enzyme which plays a role in the lipid metabolism of the liver. In addition, AFFIRIS expects to complete an exploratory Phase 1 development program in three ongoing clinical trials with its active immunotherapy candidates PD01A and PD03A targeting oligomeric forms of alpha synuclein in Parkinson’s and Multiple System Atrophy (MSA) patients in Q4 2017. AFFIRIS enjoys the continuous support of The Michael J. Fox Foundation, the world’s largest nonprofit funder of Parkinson’s research.

About AFFIRIS AG:
On the basis of its proprietary patented AFFITOME®-technology, AFFIRIS develops tailor-made active immunotherapies against chronic diseases. Its clinical pipeline consists of 3 active immunotherapeutic candidates against Parkinson’s, MSA and Hypercholesterolemia. Further candidates against diabetes, allergies, asthma as well as Huntington’s disease are in preclinical development. AFFIRIS has been able to attract funding of approx. €146m to date, half of which comes from license income and government grants. AFFIRIS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.

www.affiris.com